Alison Stevenson, Managing Director and Head of R&D at Tor-Bac, explains why this single-dose product has experienced year-on-year sales growth since its introduction to the UK market in 2018. Stevenson explains: “Practitioners offering injectable procedures are familiar with using bacteriostatic …
Subscriber content
Continue reading this clinical article
To read this post in full you need an Aesthetics Journal subscription. Choose the plan that fits your practice — every paid plan includes the complete peer-reviewed clinical library and CPD-accredited learning.
Already a subscriber? Log in
